Vol. 1 No. 5: Changing the paradigm: new perspectives in the treatment of haematological malignancies | Hematology Meeting Reports (formerly Haematologica Reports)

Current Issue

Vol. 1 No. 5

17 June 2009

View this Issue

Vol. 1 No. 5: Changing the paradigm: new perspectives in the treatment of haematological malignancies

Published: 17 June 2009

Articles

Introduction

Emili Montserrat

https://doi.org/10.4081/hmr.v1i5.633

187

PDF: 132
- PDF
Progress and prognosis in chronic lymphocytic leukaemia

Stephan Stilgenbauer

https://doi.org/10.4081/hmr.v1i5.634

180

PDF: 314
- PDF
Fludarabine plus cyclophosphamide combination: a new standard for first-line therapy in chronic lymphocytic leukaemiaa

Peter Hillmen

https://doi.org/10.4081/hmr.v1i5.635

205

PDF: 399
- PDF
Consolidation therapy with alemtuzumab prolongs remission of chronic lymphocytic leukaemia

Clemens-Martin Wendtner

https://doi.org/10.4081/hmr.v1i5.636

229

PDF: 310
- PDF
Combination therapy with alemtuzumab: existing data and future studies

Robin Foà

https://doi.org/10.4081/hmr.v1i5.637

178

PDF: 202
- PDF
The role of alemtuzumab in chronic lymphocytic leukaemia patients with p53 defects

Andrew R. Pettitt

https://doi.org/10.4081/hmr.v1i5.638

209

PDF: 505
- PDF
Advances in the management of follicular lymphoma

Michele Ghielmini

https://doi.org/10.4081/hmr.v1i5.639

193

PDF: 294
- PDF
Radioimmunotherapy in non-Hodgkin’s lymphoma: can it change the course of the disease?

Timothy Illidge

https://doi.org/10.4081/hmr.v1i5.640

296

PDF: 286
- PDF
Where does 90Y-ibritumomab tiuxetan radioimmunotherapy fit? Selecting the right patient

Martin Bentz

https://doi.org/10.4081/hmr.v1i5.641

235

PDF: 433
- PDF
United for success against non-Hodgkin’s lymphoma: role and responsibilities of the nuclear medicine department

John Buscombe

https://doi.org/10.4081/hmr.v1i5.642

181

PDF: 242
- PDF
Diffuse large B-cell lymphoma: the curable disease?

Michael Pfreundschuh

https://doi.org/10.4081/hmr.v1i5.643

369

PDF: 1474
- PDF
New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma

Franck Morschhauser

https://doi.org/10.4081/hmr.v1i5.644

187

PDF: 336
- PDF
An update on90Y-ibritumomab tiuxetan in autologous stem cell transplantation

Christian Gisselbrecht

https://doi.org/10.4081/hmr.v1i5.645

177

PDF: 327
- PDF

© PAGEPress 2008-2025 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy